Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment

Fig. 4

Combination of dasatinib and a subtherapeutic dose of Infliximab completely abolishes arthritis pathology and its related valvular pathology. a Clinical arthritis score depicting the synergistic therapeutic effect of a combination of different doses of dasatinib with 1 mg/Kg of Infliximab, in comparison to two doses of Infliximab (** p-value < 0.01; *** p-value ≤ 0.0001). All data are shown as mean ± SEM and all comparisons were made against vehicle. b Representative histology images depicting the amelioration of Tg197 arthritis symptoms and valvular pathology following treatment with dasatinib alone or in combination with a low dose of Infliximab. Hind limb paraffin sections are stained with H&E for the evaluation of synovitis, toluidine blue for the evaluation of cartilage destruction and TRAP for the evaluation of osteoclast numbers and bone erosion. Longitudinal heart paraffin sections are stained with H&E for the evaluation of the valvular pathology. [Right panel scale bar: 500 μm, left panel scale bar: 1 mm (AO: Aorta, AoV: Aortic valve, LV: left ventricle)]. c Individual histopathological arthritis scores depicting the synergistic therapeutic effect of a combination of different doses of dasatinib with 1 mg/Kg of Infliximab, in comparison to two doses of Infliximab (* p-value < 0.05; *** p-value ≤ 0.0001). All data are shown as mean ± SEM and all comparisons were made against vehicle

Back to article page